BI 853520

DRUG2 trials

Sponsors

Boehringer Ingelheim

Conditions

Neoplasms

Phase 1

A Study of BI 853520 in Patients With Various Types of Advanced or Metastatic Cancer

CompletedNCT01335269

Boehringer IngelheimNeoplasms

Start: 2011-07-31End: 2015-12-31Updated: 2015-12-09

A Study of BI 853520 in Japanese and Taiwanese Patients With Various Types of Advanced or Metastatic Cancer

CompletedNCT01905111

Boehringer IngelheimNeoplasms

Start: 2013-07-31End: 2014-08-31Updated: 2014-09-04

Related Papers

Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies.

2019-02-0145 citations

Phase I Study of the Focal Adhesion Kinase Inhibitor BI 853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors.

2019-02-0126 citations

Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520.

2019-02-016 citations

A phase I study of BI 853520, an inhibitor of focal adhesion kinase (FAK), in patients with advanced or metastatic solid tumors.

Journal of Clinical Oncology2015-05-202 citations